| Subject: | FDA and Eli Lilly Announce Precaution Revisions for Cymbalta |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 24 Oct 2005 - 11:43 am |
| Audience: Neuropsychiatric and other healthcare professionals
Eli Lilly and The Food and Drug Administration (FDA) notified healthcare professionals of revisions to the PRECAUTIONS/ Hepatotoxicity section of the prescribing information for Cymbalta (duloxetine hydrochloride), indicated for treatment of major depressive disorder and diabetic peripheral neuropathic pain.
Postmarketing reports of hepatic injury, including hepatitis and cholestatic jaundice, suggest that patients with... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
REFERENCES:
Policies / Forms / Additional Resources:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
